ChemoCentryx ContactSite Map
News & Events

Overview

Corporate Governance

Annual Reports

SEC Filings


Stock Information

Press Releases

Events & Presentations

contact Info

FAQs

Shareholder Tools

ChemoCentryx is a biopharmaceutical company focused exclusively on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. Our drug candidates target specific chemokines or chemo-attractant receptors, thereby blocking the inflammatory response driven by that particular chemokine while leaving the rest of the immune system unaffected. Our goal is to discover, develop and commercialize therapeutics with distinct advantages over currently marketed therapies in our disease areas of focus, thereby maximizing shareholder value.

Stock Chart
Stock price graph
     
Stock Quote
NASDAQ: CCXI
Price:
5.35
Change:
+ 0.05
Day High:
5.41
Day Low:
5.20
Volume:
123,900
4:00 PM ET on Apr 17, 2014
Delayed at least 20 minutes.
Provided by eSignal.

View all »   RSSRecent News

Mar 27, 2014
ChemoCentryx Appoints Anne-Marie S. Duliege, M.D., M.S. to Chief Strategic Development Role and Head of Immuno-Oncology

Mar 13, 2014
ChemoCentryx Announces Financial Results for the Quarter and Year Ended December 31, 2013

Mar 3, 2014
ChemoCentryx to Hold Fourth Quarter and Year-End 2013 Financial Results Conference Call on Thursday, March 13, 2014

^ Return to Top